Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
- 1 March 2011
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 10 (3) , 221-229
Abstract
No abstract availableKeywords
Funding Information
- ACADIA Pharmaceuticals
- National Institute of Mental Health
- Ministero dell’Istruzione, dell’Università e della Ricerca
- National Parkinson Foundation
- Genzyme
- Schering-Plough
- Novartis
This publication has 18 references indexed in Scilit:
- Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disordersExperimental Neurology, 2010
- Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuationsMovement Disorders, 2008
- Adverse Events from the Treatment of Parkinson's DiseaseNeurologic Clinics, 2008
- Caffeine and Progression of Parkinson DiseaseClinical Neuropharmacology, 2008
- A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson diseaseNeurology, 2008
- Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)Annals of Neurology, 2008
- Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidinesBioorganic & Medicinal Chemistry Letters, 2007
- Parkinson's disease home diary: Further validation and implications for clinical trialsMovement Disorders, 2004
- Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter‐ and intrarater reliability assessmentMovement Disorders, 1994
- Striatal Restricted Adenosine A2 Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry StudyJournal of Neurochemistry, 1991